{"text": ["AbbVie", "Stock", "Could", "Become", "a", "New", "Happy", "Pill", "for", "Investors"], "created_at": "2018-12-03 19:25:09"}
{"text": ["IMBRUVICA\u00ae", "(ibrutinib)", "Phase", "3", "Combination", "Data", "with", "Obinutuzumab", "Finds", "Significant", "Improvement", "in", "Progression-Free", "Survival", "(PFS)", "Over", "Standard", "Chemoimmunotherapy", "of", "Chlorambucil", "Plus", "Obinutuzumab", "for", "Previously", "Untreated", "Chronic", "Lymphocytic", "Leukemia/Small", "Lymphocytic", "Lymphoma", "(CLL/SLL)"], "created_at": "2018-12-03 19:17:00"}
{"text": ["XLV,", "PFE,", "MRK,", "ABBV:", "ETF", "Inflow", "Alert"], "created_at": "2018-12-03 18:09:39"}
{"text": ["XLV,", "PFE,", "MRK,", "ABBV:", "ETF", "Inflow", "Alert"], "created_at": "2018-12-03 18:09:39"}
{"text": ["AbbVie", "Settles", "With", "Pfizer", "for", "Humira", "Biosimilar", "in", "U.S."], "created_at": "2018-12-03 17:09:40"}
{"text": ["AbbVie", "Settles", "With", "Pfizer", "for", "Humira", "Biosimilar", "in", "U.S."], "created_at": "2018-12-03 17:09:40"}
{"text": ["AbbVie's", "Imbruvica", "Achieves", "Up", "to", "7-Year", "Progression-Free", "Survival", "in", "Leukemia", "Patients"], "created_at": "2018-12-03 16:52:41"}
{"text": ["AbbVie", "Presents", "Long-Term", "Data", "on", "Cancer", "Drugs", "at", "ASH", "2018"], "created_at": "2018-12-03 16:12:12"}
{"text": ["AbbVie", "Presents", "Long-Term", "Data", "on", "Cancer", "Drugs", "at", "ASH", "2018"], "created_at": "2018-12-03 16:12:12"}
{"text": ["AbbVie", "Settles", "With", "Pfizer", "for", "Humira", "Biosimilar", "in", "U.S."], "created_at": "2018-12-03 14:55:02"}
{"text": ["AbbVie", "Presents", "Long-Term", "Data", "on", "Cancer", "Drugs", "at", "ASH", "2018"], "created_at": "2018-12-03 14:00:02"}
{"text": ["Today's", "Research", "Reports", "on", "Trending", "Tickers:", "AbbVie", "and", "OPKO", "Health"], "created_at": "2018-12-03 12:00:00"}
